CN104039313A - 缓释制剂 - Google Patents

缓释制剂 Download PDF

Info

Publication number
CN104039313A
CN104039313A CN201280062591.4A CN201280062591A CN104039313A CN 104039313 A CN104039313 A CN 104039313A CN 201280062591 A CN201280062591 A CN 201280062591A CN 104039313 A CN104039313 A CN 104039313A
Authority
CN
China
Prior art keywords
pioglitazone
sustained
polyethylene oxide
average molecular
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062591.4A
Other languages
English (en)
Chinese (zh)
Inventor
田上宽
村川佑介
石井友美子
竹中薰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104039313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN104039313A publication Critical patent/CN104039313A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280062591.4A 2011-10-21 2012-10-19 缓释制剂 Pending CN104039313A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
JP2011-232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
CN104039313A true CN104039313A (zh) 2014-09-10

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062591.4A Pending CN104039313A (zh) 2011-10-21 2012-10-19 缓释制剂

Country Status (30)

Country Link
US (1) US9907789B2 (https=)
EP (1) EP2768487B1 (https=)
JP (1) JP6093762B2 (https=)
KR (1) KR20140081826A (https=)
CN (1) CN104039313A (https=)
AP (1) AP2014007645A0 (https=)
AR (1) AR088398A1 (https=)
AU (1) AU2012326976B2 (https=)
BR (1) BR112014008744A2 (https=)
CA (1) CA2852417A1 (https=)
CL (1) CL2014000992A1 (https=)
CO (1) CO6960544A2 (https=)
CR (1) CR20140213A (https=)
DO (1) DOP2014000077A (https=)
EA (1) EA201490840A1 (https=)
EC (1) ECSP14013328A (https=)
IL (1) IL232114A0 (https=)
IN (1) IN2014DN03169A (https=)
MA (1) MA35717B1 (https=)
MX (1) MX2014004679A (https=)
NZ (1) NZ624275A (https=)
PE (1) PE20141189A1 (https=)
PH (1) PH12014500856A1 (https=)
SG (2) SG2014012025A (https=)
TN (1) TN2014000152A1 (https=)
TW (1) TW201323018A (https=)
UA (1) UA113858C2 (https=)
UY (1) UY34403A (https=)
WO (1) WO2013058409A1 (https=)
ZA (1) ZA201403103B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091004A (zh) * 1992-09-18 1994-08-24 山之内制药株式会社 水凝胶缓释剂
WO2000032190A1 (en) * 1998-11-27 2000-06-08 Case Western Reserve University Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
CN101884627A (zh) * 2010-07-07 2010-11-17 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
CN102170878A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 控释药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (https=) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
TW200510002A (en) 2003-06-06 2005-03-16 Takeda Chemical Industries Ltd Solid pharmaceutical preparation
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JP2008511609A (ja) 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
WO2007038115A2 (en) 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
WO2007114376A1 (ja) 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. 固形医薬製剤
JP2009534292A (ja) 2006-04-27 2009-09-24 武田薬品工業株式会社 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091004A (zh) * 1992-09-18 1994-08-24 山之内制药株式会社 水凝胶缓释剂
WO2000032190A1 (en) * 1998-11-27 2000-06-08 Case Western Reserve University Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
CN102170878A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 控释药物组合物
CN101884627A (zh) * 2010-07-07 2010-11-17 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王文苹 等: "聚氧乙烯骨架缓释片的处方及体外释药机制研究", 《中国现代应用药学》 *
聂淑芳 等: "聚氧乙烯亲水凝胶骨架片的溶蚀行为", 《药学学报》 *

Also Published As

Publication number Publication date
TW201323018A (zh) 2013-06-16
AU2012326976A1 (en) 2014-05-29
NZ624275A (en) 2016-09-30
IN2014DN03169A (https=) 2015-05-22
SG2014012025A (en) 2014-06-27
EP2768487A1 (en) 2014-08-27
JP2014530802A (ja) 2014-11-20
UA113858C2 (uk) 2017-03-27
KR20140081826A (ko) 2014-07-01
CL2014000992A1 (es) 2014-09-05
CR20140213A (es) 2014-06-18
SG10201700121YA (en) 2017-03-30
UY34403A (es) 2013-05-31
BR112014008744A2 (pt) 2017-04-18
ECSP14013328A (es) 2014-05-31
PE20141189A1 (es) 2014-09-24
US9907789B2 (en) 2018-03-06
AP2014007645A0 (en) 2014-05-31
ZA201403103B (en) 2015-08-26
MA35717B1 (fr) 2014-12-01
CA2852417A1 (en) 2013-04-25
MX2014004679A (es) 2014-08-01
WO2013058409A1 (en) 2013-04-25
AU2012326976B2 (en) 2017-08-17
DOP2014000077A (es) 2014-07-15
AU2012326976A2 (en) 2014-06-12
JP6093762B2 (ja) 2017-03-08
IL232114A0 (en) 2014-06-30
EA201490840A1 (ru) 2014-08-29
US20140248362A1 (en) 2014-09-04
CO6960544A2 (es) 2014-05-30
EP2768487B1 (en) 2020-06-03
AR088398A1 (es) 2014-05-28
TN2014000152A1 (en) 2015-09-30
PH12014500856A1 (en) 2014-05-19

Similar Documents

Publication Publication Date Title
EP3641742B1 (en) Hydroxynorketamine for the use in the treatment of depression
JP4688089B2 (ja) 放出制御医薬組成物
CN104039313A (zh) 缓释制剂
CN101969931A (zh) 包含霉酚酸的调节释放药物组合物及其方法
JPWO2014034860A1 (ja) 経口投与用医薬組成物
JP2023513249A (ja) オメカムチブメカルビル製剤
JP2016188181A (ja) ミラベグロン含有放出制御錠剤
CN103945831A (zh) 医药制剂
TW202038917A (zh) 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法
JP2017523149A (ja) エドキサバンの医薬組成物
EP2987489A1 (en) Controlled-release drug formulation
CN102958514A (zh) 口腔内崩解片剂
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
US10420764B2 (en) Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
US10335376B2 (en) Raloxifene sprinkle composition
TW201729814A (zh) 固形製劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication